New-onset uveitis during CTLA-4 blockade therapy with ipilimumab in metastatic melanoma patient

Canadian Journal of Ophthalmology

Volumn 50, Issue 1, 2015, Pages e2-e4

  Miserocchi, Elisabetta ^a   Cimminiello, Carolina ^a   Mazzola, Marco ^a   Russo, Vincenzo ^a   Modorati, Giulio M ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FOTEMUSTINE; IPILIMUMAB; PREDNISOLONE ACETATE; TROPICAMIDE; ANTINEOPLASTIC AGENT; CTLA4 PROTEIN, HUMAN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GLUCOCORTICOID; MONOCLONAL ANTIBODY; MYDRIATIC AGENT; PREDNISOLONE;

AGED; BIOMICROSCOPY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CASE REPORT; DRUG SAFETY; EYE EXAMINATION; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IRIDOCYCLITIS; LETTER; LIVER BIOPSY; LIVER METASTASIS; METASTATIC MELANOMA; MULTIPLE CYCLE TREATMENT; SLIT LAMP; UVEA MELANOMA; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; LIVER NEOPLASMS; MELANOMA; PATHOLOGY; SECONDARY; UVEAL NEOPLASMS; UVEITIS, ANTERIOR; VISION DISORDERS; VISUAL ACUITY;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CTLA-4 ANTIGEN; FEMALE; GLUCOCORTICOIDS; HUMANS; LIVER NEOPLASMS; MELANOMA; MYDRIATICS; PREDNISOLONE; TROPICAMIDE; UVEAL NEOPLASMS; UVEITIS, ANTERIOR; VISION DISORDERS; VISUAL ACUITY;

EID: 84922976477     PISSN: 00084182     EISSN: 17153360     Source Type: Journal    
DOI: 10.1016/j.jcjo.2014.10.010     Document Type: Letter

References (13)

1. C. Robert, and F. Ghiringhelli What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma? Oncologist 14 2009 848 861
2. Z. Hanaizi, B. van Zwieten-Boot, and G. Calvo The European Medicines Agency review of ipilimumab (Yervoy) for the treatment of advanced (unresectable or metastatic) melanoma in adults who have received prior therapy: summary of the scientific assessment of the Committee for Medicinal Products for Human Use. Eur J Cancer 48 2012 237 242
3. G. Della Vittoria Scarpati, and C. Fusciello Ipilimumab in the treatment of metastatic melanoma: management of adverse events Onco Targets Ther 7 2014 203 209
4. J. Wolchok, B. Neyns, and G. Linette Ipilimumab monotherapy in patients with previously treated, advanced melanoma: a randomized, double-blind, multicenter, phase 2, dose-ranging study Lancet Oncol 11 2010 155 164
5. J.S. Weber, R. Dummer, V. de Pril, C. Lebbé, and F.S. Hodi Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma Cancer 119 2013 1675 1682
6. R. Thurmar, and H.M. Kluger Ipilimumab: a promising immunotherapy for melanoma Oncology (Williston Park) 24 2010 1280 1288
7. L. Min, A. Vaidya, and C. Becker Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy Eur J Endocrinol 164 2011 303 307
8. G. Borodic, D.M. Hinkle, and Y. Cia Drug-induced graves disease from CTLA-4 receptor suppression Ophthal Plast Reconstr Surg 27 2011 e87 e88
9. J.S. Weber, K.C. Kähler, and A. Hauschild Management of immune-related adverse events and kinetics of response with ipilimumab J Clin Oncol 30 2012 2691 2697
10. M.R. Robinson, C.C. Chan, and J.C. Yang Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis J Immunother 27 2004 478 479
11. C. Lemechand, and H.T. Arkenau Novel treatments for metastatic cutaneous melanoma and the management of emergent toxicities Clin Med Insights Oncol 6 2012 53 66
12. T. Hager, and B. Seitz Ocular side effects of biological agents in oncology: what should the clinician be aware of? Onco Targets Ther 7 2013 69-7
13. F. Kalli, R. Machiorlatti, and F. Battaglia Comparative analysis of cancer vaccine settings for the selection of an effective protocol in mice. J Transl Med 11 2013 120